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Abstract
Background: SPARC (secreted protein acidic and rich in cysteine) is a nonstructural, cell-matrix modulating protein
involved in angiogenesis and endothelial barrier function, yet its potential role in cerebrovascular development,
inflammation, and repair in the central nervous system (CNS) remains undetermined.
Methods: This study examines SPARC expression in cultured human cerebral microvascular endothelial cells
(hCMEC/D3)—an in vitro model of the blood-brain barrier (BBB)—as they transition between proliferative and
barrier phenotypes and encounter pro-inflammatory stimuli. SPARC protein levels were quantified by Western
blotting and immunocytochemistry and messenger RNA (mRNA) by RT-PCR.
Results: Constitutive SPARC expression by proliferating hCMEC/D3s is reduced as cells mature and establish a
confluent monolayer. SPARC expression positively correlated with the proliferation marker Ki-67 suggesting a role
for SPARC in cerebrovascular development. The pro-inflammatory molecules tumor necrosis factor-α (TNF-α) and
endotoxin lipopolysaccharide (LPS) increased SPARC expression in cerebral endothelia. Interferon gamma (IFN-γ)
abrogated SPARC induction observed with TNF-α alone. Barrier function assays show recombinant human (rh)-SPARC
increased paracellular permeability and decreased transendothelial electrical resistance (TEER). This was paralleled by
reduced zonula occludens-1 (ZO-1) and occludin expression in hCMEC/D3s exposed to rh-SPARC (1–10 μg/ml)
compared with cells in media containing a physiological dose of SPARC.
Conclusions: Together, these findings define a role for SPARC in influencing cerebral microvascular properties
and function during development and inflammation at the BBB such that it may mediate processes of CNS
inflammation and repair.
Abbreviations: BBB, Blood-brain barrier; CAM, Chorioallantoic membrane; CNS, Central nervous system;
hCMEC/D3, Human cerebral microvascular endothelial cell; IFN-γ, Interferon gamma; LPS, Lipopolysaccharide; MS, Multiple
sclerosis; RT-PCR, Reverse transcription polymerase chain reaction; SPARC, Secreted protein acidic and rich in cysteine;
TGF-β, Transforming growth factor beta; TJ, Tight junctions; TNF-α, Tumor necrosis factor alpha; VCAM1, Vascular cell
adhesion molecule 1; VEGF, Vascular endothelial growth factor; ZO-1, Zonula occludens
Background
Endothelial cells play an essential role in normal homeo-
stasis of the central nervous system (CNS). In healthy
individuals, microvessels throughout most of the CNS
possess a luminal monolayer of tightly apposed endo-
thelial cells situated between the blood and brain
parenchyma comprising together with adjacent astro-
cytes the blood-brain barrier (BBB) [1]. Cerebral endo-
thelial cells are crucial for normal neurological function
as they constitute both a physical “barrier” which limits
molecular and cellular exchange between blood and
brain compartments and a “fence” which maintains po-
larity of transporters responsible for delivery of essential
nutrients and removal of potentially harmful toxins [2].
These CNS endothelia derive a low permeability barrier
due to interendothelial tight junctions (TJ) occludin and
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claudin proteins as well as junction associated submem-
branous adaptor proteins such as zonula occludens
(ZO)-1 [3]. Several studies show membrane localization
of tight junction proteins are the morphological correlate of
BBB integrity and tightness [4, 5]. Barrier disruption sec-
ondary to tight junction dysregulation results from reduced
endovascular flow [6], hypoxia/ischemia [7], and inflamma-
tory cytokines such as tumor necrosis factor-α (TNF-α) [8]
and vascular endothelial-derived growth factor (VEGF) [9].
Several CNS diseases including neoplasia, hereditary vascu-
lar malformation, trauma, and chronic inflammatory and
neurodegenerative diseases such as multiple sclerosis
(MS) feature characteristics of BBB breakdown [10, 11].
Characterizing factors able to influence BBB integrity
and aspects of vascular remodeling during CNS inflam-
mation may identify key molecules with both physio-
logical and perhaps pathological roles in disease.
BBB cytoarchitecture and response to stimuli are often
examined in a simplified treatment and effect system
comprised of in vitro cultures of endothelial cells estab-
lished from cerebral microvessels. These cells recapitulate
in vivo BBB characteristics such as expression of specific
endothelial markers (i.e., CD31 and VE-cadherin), BBB
transporters (i.e., GLUT-1, P-glycoprotein, transferrin),
and tight junction markers (i.e., ZO-1 and occludin) and
form a monolayer with low paracellular permeability and
high transendothelial electrical resistance (TEER) con-
sistent with the presence of membrane-associated tight
junctions [12–14]. In the present study, we use a well-
characterized in vitro model of the BBB consisting of
immortalized human cerebral microvascular endothelial
cells (hCMEC/D3) that express and appropriately
localize important BBB proteins characteristic of their
in vivo counterparts [15, 16].
SPARC (secreted protein acidic and rich in cysteine) is
a matricellular cell-matrix modulating protein involved
in angiogenesis [17, 18] and endothelial barrier function
[19]. Many cell types including endothelia, fibroblasts,
and macrophages constitutively express SPARC and up-
regulate its expression in tissue regions undergoing high
rates of remodeling, repair, and proliferation [20]. SPARC
is typically enriched where new blood vessels are being
formed, as evidenced using an in vivo chorioallantoic
membrane (CAM) model of angiogenesis [21]. In the
CNS, SPARC is highly expressed in developing blood
vessels at early stages of development and down-
regulated with developmental maturity (Roskams Lab,
unpublished observations). This spatiotemporal pattern
of SPARC expression is consistent with the role for
SPARC in angiogenesis and BBB establishment [22, 23].
Normal physiological levels of SPARC in healthy individ-
uals (0.1–0.8 μg/ml in plasma) are increased in neoplastic
and inflammatory conditions (1.5–10 μg/ml in plasma)
[24–26]. Increased SPARC secretion has been associated
with carcinoma [27] and other tumors [28] such as gli-
omas [29], as well as inflammatory renal disease [30, 31],
and scleroderma characterized by vascular dysfunction,
autoantibody production, and tissue fibrosis [32].
SPARC may play a role in mediating the CNS response
to injury and repair given enhanced expression in in vivo
models of CNS damage and repair. In an in vivo cortical
wound model, SPARC messenger RNA (mRNA) was
abundantly expressed in developing blood vessels prox-
imal to the wound edge days 3 to 10 post-injury, sug-
gesting its involvement in the vascular response to CNS
injury and cerebrovascular ischemia [22, 33]. Furthermore,
SPARC may be associated with neurological recovery fol-
lowing CNS injury. Proteomic screens of murine lamina
propria olfactory ensheathing cell (LP-OEC)-conditioned
media identified SPARC as the key secreted protein sup-
porting neural tissue repair after damage, capable of pro-
moting spinal cord repair by limiting gliotic scar and
cavity formation, stimulating axonal outgrowth and direct-
ing angiogenesis [34]. SPARC has been shown to promote
Schwann cell-mediated neurite outgrowth in vivo and in
vitro [34]. Moreover, SPARC-null OECs transplanted into
contused rat spinal cord reduced outgrowth of specific
subsets of sensory and supraspinal axons and impaired
immune response to injury, suggesting its role in
neural regenerative processes and the neuroimmune
response to CNS injury [34].
Altogether, its potential roles in modulating angiogenic
and barrier parameters of vascular development and
repair [19, 23, 35, 36], its expression and influence on
neural regeneration after CNS injury [33, 34], and its in-
fluence on the profile and extent of immune infiltration
[37, 38] make SPARC a molecule of particular interest in
chronic neuroinflammatory pathologies such as MS.
Methods
Reagents and antibodies
Recombinant human (rh)-SPARC (R&D Systems,
Minneapolis, MN), TNF-α (Invitrogen, Camarillo, CA),
interferon gamma (IFN-γ), (Invitrogen, Camarillo, CA),
and lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis,
MO) were obtained commercially. Antibodies for immuno-
blotting and immunocytochemistry included monoclonal
mouse anti-human SPARC IgG1 (2.5 μg/ml; Haematologic
Technologies, Essex Junction, VT), polyclonal rabbit anti-
ZO-1 IgG (1 μg/ml; Invitrogen), monoclonal mouse
anti-ZO-1 IgG1 (2.0 μg/ml; Invitrogen), monoclonal
mouse anti-occludin IgG1 (0.5 μg/ml; Zymed, Carlsbad,
CA), monoclonal mouse anti-Ki-67 IgG1 (1:100; Millipore,
Billerica, MA), and monoclonal mouse anti-human
glyceraldehyde-3-phosphate dehydrogenase IgG1 (GAPDH,
1:10,000; Santa Cruz Biotechnology, Santa Cruz, CA).
Secondary antibodies included Alexa Fluor 568 goat
anti-mouse IgG (1:200; Invitrogen); Alexa Fluor 488
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goat anti-rabbit IgG (1:200; Invitrogen); and horserad-
ish peroxidase (HRP)-conjugated goat anti-mouse IgG
(1:5000; Jackson ImmunoResearch, Burlington, ON).
Isotype-matched control abs included mouse IgG1
(2.5 μg/ml; Invitrogen) and rabbit IgG (1 μg/ml;
Invitrogen).
Cell culture
The hCMEC/D3 line was generously provided by Drs. B.
Weksler, I. Romero, and P-O. Couraud (Cochin Institute,
Paris). The cell line was established as described in
Weksler et al. 2005. hCMEC/D3s were cultured in
complete media comprised of EBM-2 media (Lonza,
Walkersville, MD) supplemented with 5 % fetal bovine
serum (FBS) (PAA Laboratories, Etobicoke, ON), 1 %
penicillin-streptomycin, 1.4 μM hydrocortisone, 5 μg/ml
L-ascorbic acid, 10 mM HEPES (all from Sigma), 1:100
chemically defined lipid concentrate (Invitrogen-Gibco),
and 1 ng/ml basic fibroblast growth factor (bFGF) (Invitro-
gen-Gibco, Grand Island, NY) at 37 °C with 5 % CO2, 95 %
air, and saturated humidity. The media was replenished
every 2 to 3 days. For immunoblotting and reverse tran-
scription polymerase chain reaction (RT-PCR), the cells
were seeded at 1.2 × 10E4 cells/cm2 on 25 cm2 flasks and
six-well plates (Corning, Corning, NY) coated with type I
rat tail collagen (150 μg/ml; Sigma). For immunocyto-
chemistry, the cells were grown on collagen type I-coated
glass coverslips or collagenous membranes in a transwell
configuration (MP Biomedicals, Solon, OH). hCMEC/D3
cells formed confluent, contact-inhibited monolayers, and
were used consistently between passages (p)28 and 35.
Growth and development of hCMEC/D3s
To test if SPARC expression changed under varied serum
conditions, confluent hCMEC/D3 cultures (p30–32) were
grown in complete growth media and replenished with
fresh medium containing either no FBS, 1 % FBS, 5 %
FBS, or 0.1 % bovine serum albumin (BSA) (Sigma) in
place of FBS. hCMEC/D3 growth was assessed for culture
confluency where cells were approximately 20–30 % con-
fluent after 1 day in culture (DIC), 50–70 % confluent
after 4 DIC, and confluent after 6–7 DIC. Protein and
mRNA was extracted from cultures at subconfluent and
confluent growth stages and subjected to immunoblotting
and semi-quantitative RT-PCR. hCMEC/D3 cultures
grown on collagen membranes were fixed in 4 % para-
formaldehyde (PFA)-PBS when subconfluent (50–70 %
confluent) and confluent, before being probed with
monoclonal antibodies against SPARC, ZO-1, and Ki-67
for immunocytochemical analysis.
hCMEC/D3 exposure to SPARC or inflammatory mediators
hCMEC/D3s cultured on collagen type I-coated six-well
plates until confluent were treated 1 day later with 0.1,
1, 10 μg/ml rh-SPARC (R&D Systems) and TNF-α
(200 U/ml) in fresh reduced serum (1 % FBS) complete
media for 24 h. The protein levels of endothelial tight
junctions were determined by Western blotting analysis.
Confluent monolayers grown on collagen membrane
inserts were replenished with complete media con-
taining 10 or 100 U/ml TNF-α, 100, 200, or 500 U/
ml IFN-γ, and 50 ng/ml LPS, alone and in combin-
ation. For cytokine treatment of cells on collagen
membranes, media containing cytokine was added to
the upper chamber.
Barrier function assays
Barrier function was examined using TEER impedance
measurements and transendothelial FITC-dextran (3 and
10 kDa) diffusion assays. hCMEC/D3 (p30–32) were
grown on transwell polyester membrane inserts (0.4-μm
porosity and 1.12 cm2 surface area, Corning Costar
#3460) in serum-reduced (1 % FBS) complete media
until 2 days post-confluence, and the measured TEER
had stabilized. Media was replenished into both upper
(luminal) and lower (abluminal) chambers; however,
cytokine- and SPARC-containing media were only ap-
plied into the upper chamber. TEER was measured daily
by EVOM-2 ohm meter using ENDOHM-12 chamber
and STX2 chopstick electrodes (World-Precision Instru-
ments, Sarasota, FL). Resistance of blank filters without
cells was subtracted from those with cells, and these
values were multiplied by the surface area of the inserts
to get the final resistance (Ω·cm2).
Endothelial monolayer permeability was studied by
measuring fluorescently labeled dextran diffusion through
a confluent monolayer of hCMEC/D3 cells grown on
transwell inserts. These studies were performed by adding
50 μg/ml dextran (3 or 10 kDa) tagged with Alexa Fluor
488 (Molecular probes, Eugene, OR) to the luminal
chamber of a transwell insert and sampling (10 μl/sam-
ple) from the abluminal chamber at 30, 60, 120, and
180 min into a 96-well plate, an equal volume of fresh
medium replaced each time. Dextran fluorescence in
the samples was measured by a microplate fluorometer
(Floroskan Ascent 374, ThermoScientific, Hudson, NH)
at 485 nm (excitation) and 525 nm (emission). Raw
values from dextran fluorescence were converted to
concentrations using a standard curve and slope of the
linear regression line. Permeability coefficient was cal-
culated as described previously [4].
Cell lysis and Western blotting
To lyse hCMEC/D3 cells grown on six-well plates, the
cells were first washed twice with cold PBS, then incu-
bated in situ on ice for 10 min in 125 μl of ice-cold NP-
lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM
EDTA, and 1 % NP-40, adjusted to pH 8.0) with fresh
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protease inhibitor and phosphatase inhibitor cocktails
added before use (Roche, Laval, QC). The cells were
then scraped and collected into tubes, triturated on ice
through a 28-Gauge needle five times and centrifuged at
13,500 rpm for 12 min at 4 °C. The supernatant was
collected as whole cell lysate and stored at −80 °C.
hCMEC/D3 cell lysis for TJ protein analysis required
stronger detergents, 125 μl of ice-cold radio-
immunoprecipitate assay (RIPA) buffer containing
20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1 %
NP-40, 0.1 % SDS, and 0.5 % sodium deoxycholate.
Protein concentrations were determined by bicincho-
ninic acid (BCA) protein assay kit (Sigma). Protein esti-
mations based on the BSA standard absorbance curve.
Lysates (20–40 μg) were diluted 1:1 in reducing 2×
Laemmli sample buffer (Bio-Rad, CA) containing 0.05 %
β-mercaptoethanol and heated at 100 °C for 5 min. The
samples were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE: 6 % gel
for ZO-1, 12 % gel for SPARC, 15 % gel for occludin and
claudin-5) for 1.5 h at 80–100 V and transferred to
nitrocellulose membranes in wet transfer buffer (25 mM
Tris, 192 mM glycine, 20 % methanol) at 90 mA over-
night at 4 °C. Immunoblots for SPARC, claudin-5, occlu-
din, and GAPDH were blocked in 5 % skim milk in Tris-
buffered saline (TBS: 1.37 M NaCl, 27 mM KCl, 0.25 M
Tris, adjusted to pH 7.4) for 1 h then incubated in
primary antibody diluted in 2 % skim milk-TBST
(TBS + 0.01 % Tween 20 (TW20)) overnight at 4 °C
(or 2 h at RT for GAPDH). After washing, HRP-
conjugated secondary antibodies diluted in 2 % skim
milk-TBST (TBS + 0.01 % TW20) were added and
then again washed in TBST. Immunoblots for detec-
tion of ZO-1 were blocked in 1 % BSA-TBST (TBS +
0.05 % TW20) for 4 h at RT and then incubated in
monoclonal anti-ZO-1 primary antibody diluted in
TBS overnight at 4 °C followed by washing in TBST
and incubation with secondary antibody. All immuno-
blots were developed in enhanced chemiluminescence
(ECL) substrate (ThermoFisher Scientific, Bothell,
WA). Band signals were detected using a Versadoc
imaging system (Bio-Rad Laboratories), and band
densities were quantified by ImageJ 1.42i software
(National Institutes of Health, Bethesda, MD).
Semi-quantitative RT-PCR
Total RNA was extracted from cell cultures using
RNeasy Mini Kit (QIAGEN Science, Toronto, ON) ac-
cording to the manufacturer’s protocol. Complementary
DNA (cDNA) was synthesized by High Capacity RNA-
to-cDNA Master Mix Kit (Applied Biosystems, Foster
City, CA). Relative quantification of PCR reactions
were performed with Platinum PCR SuperMix (Invi-
trogen) using the following primer sequences for SPARC
transcript amplification 5′-AGTGCACCCTGGAGGG-
CACC-3′ (Forward); 5′-TGCTTGATGCCGAAGCAGCC-
3′ (Reverse) and the following primers for the GAPDH
housekeeping gene 5′-AAGGCTGGGGCTCATTTGCA
G-3′ (Forward); 5′-CTGCTTCACCACCTTCTTGATG-3′
(Reverse). A semi-quantitative analysis of mRNA levels
was carried out using scans with the Bio-Rad Gel
Doc UV system (Bio-Rad Laboratories, Hercules, CA)
and differences in SPARC and GAPDH expression
were calculated by Image Lab software (Bio-Rad
Laboratories).
Immunocytochemistry
Following co-incubations, cultures were washed twice
with warm (37 °C) PBS and fixed at RT in 4 % PFA-PBS
for 10 min. Cultures were directly stored in PBS-0.01 %
sodium azide at 4 °C until stained. For staining, cultures
were washed twice with PBS then incubated for 10 min
in permeabilization-blocking buffer (0.1 % Triton X-100
and 4 % normal goat serum (NGS) in PBS). Cultures
were incubated twice for 10 min in blocking buffer (4 %
NGS-PBS) then incubated with primary antibody diluted
in blocking buffer for 1 h at RT or overnight at 4 °C.
After primary antibody incubation, cultures were washed
three times for 5 min with PBS then incubated in
specific secondary antibody in blocking buffer for
50 min in the dark. Cultures were washed twice in
PBS, stained with DAPI nuclear stain (1:10,000) in
PBS for 5 min, and again washed three times in PBS.
Membranes were excised from discs using a scalpel,
drained of excess PBS, and embedded in 10 μl of
ProLong Gold anti-fade reagent (Invitrogen) under-
neath a glass coverslip. Cultures on the glass cover-
slips were mounted cell side down on 10 μl of
ProLong Gold.
Image acquisition and analysis
Distribution analysis was performed in a blinded fashion
where cells were distinguished and coded numerically
on a DAPI image to avoid duplication and evaluated for
level of SPARC expression. SPARC immunoreactivity
levels were assigned to individual cells according to the
classification scheme and representative images in Table 1.
Fluorescence images were captured with an Axioplan 2
imaging epifluorescent microscope (Zeiss, Jena, Germany)
and Axiovision 4 software (Zeiss). Confocal micrographs
were captured with an Olympus Fluoview 1000 laser scan-
ning confocal microscope with Nomarski optics and
FV1000 Fluoview software (Olympus Corporation, Tokyo
Japan). Analysis was performed using Adobe Photoshop
extended CS3 version 10.0 or ImageJ 1.42i software (NIH)
or assessed by SPARC immunoreactivity scale. Adobe
Photoshop measurements of nuclear Ki-67 intensity were
performed by outlining individual nuclei on a DAPI/blue
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filter image using the “quick selection tool”, and measu-
ring Ki-67/green filter mean pixel intensity (MPI)—the
average intensity of all pixels within the DAPI-stained/de-
lineated nuclear regions. Ki-67 positivity was relative to a
threshold determined by blindly screening three images of
confluent and subconfluent images each and denoting
those cells negative for Ki-67. A threshold limit was set by
averaging the Ki-67 MPI of those nuclei visually deemed
Ki-67 negative (n = 59) plus three standard deviations. Ki-
67-positive nuclei were those exceeding this pre-defined
Ki-67 threshold. Quantification for SPARC immunofluo-
rescence was performed either by regional analysis, where
regions for analysis were demarcated by thresholding the
cell edge such that only the cell-covered surface area of a
field/image was assessed for MPI using ImageJ or assessed
based on the SPARC immunoreactivity scale. Cell count-
ing of DAPI-positive nuclei was performed using the
ImageJ “analyze particles” tool and automated using
ImageJ macroscript.
Statistical analysis
GraphPad Prism version 5.01 (GraphPad Software, San
Diego, CA) was used for graph synthesis and statistical
analysis. Parametric data expressed as mean ± standard
error of the mean (mean ± SEM) were analyzed by one-
way analysis of variance (ANOVA) and Newman-Keul
multiple comparison test. Non-parametric data expressed
as mean ± standard deviation (mean ± SD) were analyzed
by a Kruskall-Wallis and Dunn’s multiple comparison test.
Mann-Whitney comparison was performed on data com-
paring two non-parametric groups/treatments. SPARC
immunoblots and functional assays were analyzed by one-
way ANOVA followed by a Tukey’s honestly significant
difference (HSD) multiple comparisons analysis.
Results
The in vitro hCMEC/D3 model of the BBB
hCMEC/D3 cells grown on collagen type I-coated sur-
faces had fusiform morphology and were tightly apposed
forming monolayers with minimal overlap upon reach-
ing confluence (Fig. 1a). The cells grown on collagen
membrane inserts (primarily type I collagen with some
type IV collagen) were comparable in morphology and
growth rate to that of cells grown on type I collagen-
coated flasks or filters and thus became our preferred
culturing surface for immunocytochemistry experiments.
SPARC expression during hCMEC/D3 growth and
maturation
SPARC is known to be expressed in different tissues during
remodeling and repair [20], where SPARC expression cor-
relates with cell propagation. SPARC protein expression
here was first quantified by Western blot on cells at 20–30,
50–70, and 100 % confluency (Fig. 1a). Immunoblotting
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Fig. 1 (See legend on next page.)
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and immunocytochemistry analysis showed subconfluent
cultures had greater SPARC expression than confluent cul-
tures. SPARC expression decreased with days in culture
with greater than 50 % down-regulation as hCMEC/D3
established a confluent monolayer (Fig. 1b, c). These exper-
iments provide evidence that SPARC is highly expressed in
hCMEC/D3 cells during proliferative stages of growth and
down-regulated as cells establish a monolayer and become
contact inhibited.
To investigate SPARC expression during hCMEC/D3
growth and as cells develop an in vitro BBB phenotype,
cultures were fixed when approximately 50–70 % con-
fluent (subconfluent) and confluent then subjected to
immunocytochemical staining. Confluency was visually
assessed by phase contrast microscopy. Barrier pheno-
type was confirmed by peripheral localization of ZO-1,
a marker of tight junction formation. In subconfluent
cultures, cells exhibited perinuclear and dense cytoplas-
mic ZO-1 staining with ZO-1 rarely limited peripher-
ally to cell borders (Fig. 1d). Conversely, confluent cells
exhibited tightly apposed monolayers with minimal
overlap (Fig. 1a, d) and ZO-1 bands delineating the
cytoplasmic membrane in the majority of cells (Fig. 1d).
Immunocytochemical analyses revealed that SPARC
levels were heterogeneous among hMEC/D3 cells in
culture. The intensity of SPARC expression (negligible,
low, moderate, or high) in the subconfluent and conflu-
ent cultures was assessed on confocal images. The sub-
confluent cells predominantly exhibited low, moderate,
and some high SPARC levels compared to the confluent
cultures which were largely (~80 %) negligible while the
remainder of cells were low in SPARC expression
(Fig. 1e, f ).
SPARC expression was also examined on high-resolution
confocal micrographs by quantifying the global mean
pixel intensity of the images. SPARC intensity was mea-
sured in subconfluent and confluent cultures within a
300 μm × 300 μm field on images pooled from replicate
wells reported as relative mean pixel intensity ± stand-
ard deviation (MPI ± SD). SPARC intensity was greater
in regions of subconfluent culture (3.85 ± 0.492) than
regions of confluent culture (2.83 ± 0.426). Confocal
micrographs revealed that subconfluent cultures with
low and discontinuous ZO-1 staining at cell borders
have greater SPARC immunoreactivity than confluent
cultures which showed intense ZO-1 banding at cell-
cell contacts (Fig. 1d) and minimal SPARC expression
(Fig. 1d).
SPARC expression correlates with the proliferation
marker Ki-67
The Ki-67 protein (also known as MKI67) is a cellular
marker for proliferation present during all active phases
of the cell cycle (G1, S, G2, and mitosis) but typically ab-
sent from resting cells (G0) [39, 40]. Consistent with a
relatively quiescent versus proliferative state, cells from
confluent cultures had a significantly reduced percentage
of Ki-67-positive or bright cell nuclei than subconfluent
cultures (Fig. 2a, P = 0.01). The immortalized nature of
this cell line would be consistent with lower, often
speckled or punctate, but not negligible incidence of Ki-
67 staining in confluent cultures. To further examine as-
sociations between relative SPARC expression and Ki-67
reactivity in individual cells, we focused on subconfluent
cells which had SPARC expression in all ranges of our
classification scheme. Notably, cells in subconfluent cul-
tures with negligible, low, or moderate to high levels of
SPARC expression demonstrated significantly increasing
frequencies of Ki-67-positive or bright cell nuclei (Fig. 2b;
P < 0.0001). Representative images demonstrate that cells
in confluent cultures were more likely to demonstrate
colocalization of SPARC along with brighter Ki-67 stain-
ing; conversely, confluent cultures showed faint SPARC
staining and fewer Ki-67 bright cells than observed in
subconfluent hCMEC/D3 (Fig. 2c).
SPARC expression is influenced by serum conditions
Serum has been defined as a potential stimulatory and
mitogenic factor for cells in primary culture as well as
cell lines in vitro [41]. The ability of hCMEC/D3 cul-
tures to fare well in reduced serum allowed us to exam-
ine the effects of serum dose on SPARC expression. Five
percent serum-supplemented media recommended for
hCMEC/D3 cell line expansion produced the highest
(See figure on previous page.)
Fig. 1 SPARC expression is associated with proliferation of immature hCMEC/D3 and decreased as cells mature and reach confluence. a Confluency
and monolayer intactness were visually assessed by phase contrast microscopy. b, c hCMEC/D3 cultures 20–30, 50–70, and 100 % confluent were
analyzed for SPARC protein expression by immunoblotting. Data is pooled from two independent experiments, error bars represent standard error of
the mean (SEM) with statistical significance by one-way ANOVA and Tukey’s comparison test **P < 0.001; ***P < 0.0001. d Representative confocal
micrograph images show greater perinuclear and cytoplasmic SPARC staining (red) in subconfluent cultures compared to confluent cultures.
Subconfluent cultures exhibit discontinuous peripheral ZO-1 bands (green), whereas confluent cells were tightly apposed and organized into
monolayers with continual ZO-1 bands at interendothelial borders. Scale bar = 30 μm. e The individual cells in confluent monolayers express
less SPARC than the cells in subconfluent cultures. Levels of SPARC immunoreactivity (negligible, low, moderate, or high) were assigned according to
Table 1 (Additional file 1: Figure S1). Bars represent the average of results from n = 18 and n = 10 images enumerated for low, medium, or high levels
in subconfluent (empty bar) vs. confluent (filled bar) cultures in replicate wells. f Summary of individual cell staining classification from both Fig. 1e
(exp. A) and a second experiment (exp. B) with similar findings for the distribution of cells from (S) subconfluent vs. (C) confluent cultures
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observed levels of SPARC protein. One percent serum
also significantly increased SPARC compared to media
lacking serum (Fig. 3a, b). Culturing cells in 0.1 % BSA
resulted in SPARC expression more comparable to
levels observed in serum-free cultures (Fig. 3a, b).
These data clearly demonstrate that SPARC expression
in hCMEC/D3 cells is influenced by serum concentra-
tion in culture media. To enhance our sensitivity to
detect increases in SPARC expression secondary to
inflammatory stimuli, subsequent treatment experi-
ments were carried out in the presence of 1 % serum
where constitutive SPARC expression was demon-
strated to be low.
Inflammatory mediators regulate SPARC expression
in hCMEC/D3s
Our in vitro approach allowed us to model the influence
of specific inflammatory molecules on cell morphology
Fig. 2 SPARC expression positively correlates with a marker of proliferation Ki-67. a Representative immunocytochemistry images of subconfluent
hCMEC/D3 show greater SPARC expression and higher proportions of Ki-67-positive cell nuclei than confluent cultures. Images represent SPARC
staining (red) alone (upper panel) or merged with Ki-67 staining (green) in the lower panel. Data represents one of two replicate experiments. Scale
bar = 30 μm. b Percentage of cells positive for the proliferation marker Ki-67 in the subconfluent hCMEC/D3 is greater than that of the confluent
cultures. Confluent hCMEC/D3 in two experiments had significantly (exp. A: P = 0.0143; exp. B: P = 0.0017) lower incidence of Ki-67-positive nuclei
than the subconfluent cultures. Bars represent the average of results (20 images from triplicate subconfluent wells and 8 images from duplicate
confluent wells) grown on collagen membranes ± standard deviation (SD). Mann-Whitney comparison test, **P < 0.001. c SPARC levels positively
correlated with the percent of Ki-67-positive cell nuclei in subconfluent hCMEC/D3 cultures. Ki-67 staining is significantly different between groups
classified according to increasing levels of SPARC staining from negligible to low through moderate and high combined (P < 0.0001). Bars
represent the average of results from n = 20 images pooled from triplicate wells. Error bars indicate SEM. Data represents one of the two experiments
with similar significant results. One-way ANOVA and Tukey’s multiple comparison test, **P < 0.001, ***P < 0.0001
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and SPARC expression at the BBB. hCMEC/D3 cultures
grown to confluence were incubated for 12, 24, and 48 h
with TNF-α, IFN-γ, or LPS, alone or in combination.
SPARC expression patterns were studied after treatment
with pro-inflammatory cytokines TNF-α and IFN-γ, im-
plicated in the pathogenesis of several CNS inflamma-
tory disorders and the endotoxin LPS, a primary
component of the bacterial cell wall known to stimulate
the innate immune response to infection. Cell conflu-
ence and morphology was assessed by phase contrast
and ZO-1 immunofluorescence. SPARC expression was
quantified by immunofluorescence and immunoblotting.
Untreated cultures showed tightly apposed cells with
minimal overlap at the time of treatment and regular fu-
siform morphology throughout the treatment period.
Treatment with pro-inflammatory mediators resulted in
elongated morphology and whirling into circular pat-
terns along with a disruption in peripheral ZO-1 staining
(data not shown). SPARC immunoreactivity was minimal
in untreated confluent cultures maintained in serum-
reduced media (Fig. 4a, d) and significantly increased
following exposure to 10 and 100 U/ml TNF-α for 24 to
48 h (Fig. 4a). 50 ng/ml LPS treatment induced SPARC
levels to that observed for 100 U/ml TNF-α alone, while
10 ng/ml LPS had no effect (Fig. 4b, d). Interestingly,
100 U/ml TNF-α and 100 U/ml IFN-γ co-treatment ab-
rogated SPARC induction otherwise observed for TNF-α
alone at 24 and 48 h (Fig. 4a, d).
The modulatory effect of IFN-γ on SPARC expression
in hCMEC/D3 cells was temporally delayed. Significant
decreases in SPARC protein level were not observed
until 48 h of IFN-γ treatment (Fig. 4c) However, the
decrease in SPARC expression in response to a combi-
nation of IFN-γ (100 U/ml) and TNF-α (100 U/ml) was
evident much earlier at 12 h (data not shown) and sig-
nificant as early as 24 h. We further analyzed the effects
of various concentrations of IFN-γ on SPARC protein
level. To our surprise, higher concentrations of IFN-γ
(200, 500 U/ml) did not significantly change SPARC ex-
pression at 24 h and was comparable to 100 U/ml at
48 h compared to untreated controls. Taken together,
these results show that TNF-α alone or LPS consistently
increased intracellular SPARC protein expression, while
IFN-γ alone or in combination with TNF-α limits its en-
hancement in hCMEC/D3 cells. SPARC expression was
also analyzed at the individual cell level (Fig. 4d) and
across areas of confluent cells (Fig. 4e). SPARC
expression as measured by mean pixel intensity was
significantly increased in cells treated with TNF-α
alone or with LPS alone, which correlated well with
Western blot data. Treatment of hCMEC/D3 cultures
with TNF-α did up-regulate SPARC mRNA expression
in a dose-dependent manner where only 100 U/ml
TNF-α reached significance in the time studied.
Exogenous SPARC treatment increases cerebral
endothelial barrier permeability
Secreted SPARC binds matrix components of the base-
ment membrane and modulates cell-matrix interactions
thought to affect endothelial barrier function [42]. Direct
evidence suggests that SPARC increases transendothelial
permeability of hCMEC/D3 monolayers and may play a
role in modulating BBB permeability. To understand the
role of exogenous SPARC on modulating BBB integrity,
rh-SPARC was applied to hCMEC cultured on transwell
inserts 1 day post-confluence. SPARC treatment was
performed in serum-reduced media with 1 % FBS to
limit endogenous SPARC production (compared to
that observed with higher serum conditions). We as-
sumed that a lower endogenous SPARC level might
clarify the effect of exogenously supplied SPARC on
permeability.
TEER on hCMEC/D3 remained relatively low through-
out this study. It is documented that hCMEC/D3 cultures
have low TEER under static conditions [6, 16]. Baseline
TEER recordings were between 20 and 25Ω·cm2 by
ENDOHM-12 chambers and 55–60Ω·cm2 by STX2
chopstick recordings across untreated hCMEC/D3 mono-
layers. Application of rh-SPARC decreased TEER in a
concentration-dependent manner (Fig. 5a). Significant
TEER reduction was seen only at our greatest SPARC con-
centration tested of 10 μg/ml at 24 h but was still only
about half of the TEER change observed following TNF-α
(200 U/ml) treatment.
Fig. 3 a, b Growth media serum concentration influences SPARC
expression in confluent hCMEC/D3 cells. SPARC protein levels were
quantified by western blot analysis of lysates derived from cultures
propagated in media with varied serum concentration. Relative SPARC
protein levels were normalized to GAPDH. SPARC detected in lysates
resolved at the molecular weight observed for rh-SPARC (~43 kDa).
Bars represent the average of four immunoblots, two independent
experiments (exps. A and B) performed in duplicate. Error bars indicate
SEM. One-way ANOVA and Tukey’s multiple comparison test, *P < 0.05
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Fig. 4 (See legend on next page.)
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Cultures used to measure TEER were also used in
FITC-dextran diffusion permeability assays. Microvascular
cerebral endothelia partially comprise the BBB and form a
functional barrier interface between blood and neural
parenchyma regulating vital functions such as fluid-ion
balance and essential nutrient delivery. Addition of ex-
ogenous SPARC increased the permeability of hCMEC/
D3 monolayers as measured by increased FITC-dextran
diffusion after 24 h. This increase was concentration
dependent where more SPARC produced a greater in-
crease in permeability to both 3- and 10-kDa dextrans
(Fig. 5b). A dose of SPARC greater than 0.01 μg/ml
SPARC was sufficient to increase the permeability of
hCMEC/D3 monolayers. Our studies show that SPARC
has direct effects on properties of the blood-brain barrier.
Because TNF-α was also able to drive SPARC expression,
we addressed whether or not SPARC may be contributing
to TNF-α-mediated changes in permeability. Testing a
variety of monoclonal as well as polyclonal antibodies
for their potential to neutralize SPARC, we were not
able to significantly influence TNF-α mediated changes
in EC permeability detected by dextran diffusion (data
not shown). In this regard, the primary TNF-α induced
alterations in BBB permeability would seem to occur
independent of SPARC.
SPARC alters tight junction protein levels in hCMEC/D3s
To test the ability of SPARC to alter BBB-associated
tight junction protein expression, hCMEC/D3 mono-
layers were treated with rh-SPARC (0.1, 1, 10 μg/ml) or
TNF-α (200 U/ml), the latter being a well-characterized
modulator of TJ expression in BBB endothelial cells,
including hCMEC/D3 cells [16]. Phase contrast mi-
crographs of TNF-α and SPARC-treated hCMEC/D3
monolayers showed cultures remained intact under all
treatment conditions and retained regular fusiform
morphology and apposition with minimal overcrowding
and no apparent lifting or dissociation (data not shown).
Previous studies of BBB integrity and TJ expression have
described a barrier-promoting/protecting property for
hydrocortisone [4]; hydrocortisone was included at doses
recommended by the hCMEC/D3 providers based on
publications testing its influence on barrier phenotype.
Cell morphology and growth appeared similar in the
presence or absence of hydrocortisone after 24 h (data
not shown).
Addition of TNF-α decreased total expression of all TJ
proteins studied (Fig. 6a). TNF-α treatment of hCMEC/
D3s lowered the expression of ZO-1 (0.76, P = 0.013)
and occludin (0.62, P = 0.044) compared to controls. The
addition of hydrocortisone to the media with TNF-α
returned ZO-1 expression to baseline levels, but was not
effective at restoring occludin levels to that of untreated
cells when in the presence of TNF-α (data not shown).
Our experiments revealed that hCMEC/D3 cells in
culture produced low levels of SPARC even under resting
conditions, suggesting that levels of SPARC in culture
closely model the physiological levels of SPARC detected
in the plasma and serum of healthy individuals (ranging
from 0.1 to 0.5 μg/ml). In this regard, it is difficult to
assess the physiological relevance of comparing cells
cultured in “0” or “no SPARC” conditions which would
exist immediately following media replacement.
Exogenous SPARC was applied at physiological levels
of 0.1 μg/ml and at supraphysiological levels observed
in individuals with various inflammatory disorders.
Functional studies using FITC-dextran (3 and 10 kDa)
diffusion and TEER showed that rh-SPARC treatment in-
creases transendothelial permeability of hCMEC/D3 mono-
layers in a concentration-dependent manner (Fig. 5b, c),
confirming barrier disruption in cerebral monolayers
when exposed to SPARC in physiological (0.1 μg/ml)
and supraphysiological (1–10 μg/ml) concentrations.
Furthermore, we were also interested in whether
SPARC altered TJ expression at the BBB. Increasing
concentrations of exogenous SPARC from 0.1 to 1 μg/ml
(See figure on previous page.)
Fig. 4 Inflammatory mediators differentially regulate SPARC expression in hCMEC/D3 monolayers. hCMEC/D3 were incubated for 24 and 48 h in
replenished media with TNF-α, IFN-γ, or LPS, alone or in combination. a Compared to untreated/control conditions, 10 and 100 U/ml TNF-α treatment
alone increased SPARC expression at 24 and 48 h. Bars represent the average relative value of blots from n = 3 independent experiments. Error bars
indicate SEM. ANOVA and Tukey’s multiple comparison test, *P < 0.05. b The effect of varied concentrations of IFN-γ (100, 200, 500 U/ml) on SPARC
expression in hCMEC/D3 cultures was assessed by Western blot analysis. c LPS treatment enhanced SPARC levels in a dose-dependent manner at 24
and 48 h by Western blotting. Pooled results from two biological replicates are shown. d The effect of inflammatory mediators on SPARC expression
in confluent hCMEC/D3 cultures was assessed in parallel by quantitative immunocytochemistry with representative images shown and summary of
findings shown e. SPARC expression is shown following 100 /ml TNF-α, 100 U/ml IFN-γ, or 25 ng/ml LPS alone or in combination. Quantification was
pooled from 10 images of duplicate wells for each treatment. Untreated confluent cultures showed minimal SPARC staining at 24-h TNF-α and LPS
treatment alone increased SPARC levels after 24 h (P < 0.0001). Data represents one of the two experiments with similar results; error bars represent
SEM. One-way ANOVA and Tukey’s multiple comparison test vs. untreated controls, *P < 0.05; **P < 0.001; ***P < 0.0001. Scale bar= 30 μm. f RT-PCR
was used to quantify SPARC mRNA. 100 U/ml TNF-α treatment significantly (P < 0.05) increased SPARC mRNA expression. Bars represent the
average densitometric value from n = 4 experiments; error bars represent SEM. One-way ANOVA and Tukey’s multiple comparison test vs.
untreated controls, *P < 0.05
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lowered both ZO-1 (0.768, P < 0.05) and occludin (0.796,
P < 0.001) protein levels (Fig. 6b). Concentrations in
the range of 1 to 10 μg/ml tended to decrease ZO-1
and occludin protein levels compared to baseline
SPARC serum concentrations (approximately 0.1 μg/ml)
(Fig. 6a, b). Representative immunoblots and normalized
quantifications depict the trends observed (Fig. 6a).
Discussion
SPARC expression during cerebral endothelial growth and
barrier establishment
This is to our knowledge the first study to examine
SPARC expression and regulation in an in vitro BBB
model. This report describes novel in vitro evidence that
cerebral endothelia constitutively express SPARC during
proliferative stages of growth and down-regulate it as cells
form a monolayer and establish a BBB-like phenotype
as assessed by Western blot and quantitative immuno-
cytochemistry. This is consistent with in vivo observations
where SPARC expression was enriched in developing
cerebrovasculature yet diminished in mature vessels
(Roskams lab, unpublished observations) [22, 23, 43].
hCMEC/D3 cells in our experiments were propagated
in media containing various concentrations of serum
which reproducibly correlated with SPARC expression.
Cell cultures replenished for 24 h in media with increasing
serum concentrations were found to express increased
levels of SPARC. Serum is a known mitogen in this cell
line used as a positive control and stimulus of cell growth
and proliferation [41]. Our experiments define serum as a
positive regulator of SPARC expression in cerebral endo-
thelia during proliferative stages of growth.
We performed dual immunocytochemistry for SPARC
and a proliferation marker Ki-67 to investigate the link-
age between SPARC and endothelial proliferation—a
vital parameter of angiogenesis and cerebrovascular re-
sponse to injury. SPARC positively correlated with Ki-67
in subconfluent hCMEC/D3 cultures. Increased SPARC
immunoreactivity was associated with a higher percentage
of Ki-67-positive nuclei while confluent monolayers
shared low SPARC and low Ki-67 levels, providing a direct
correlation between SPARC expression and proliferation.
Brain endothelial cells have been shown to co-express
high levels of SPARC and the marker of proliferation
PCNA (proliferating cell nuclear antigen) in developing
but not mature brain capillaries [43]. SPARC produced by
dividing subconfluent cerebral endothelia may promote
focal adhesion disassembly and inhibit cell spreading
mediating cell migration and proliferation during CNS
angiogenesis [44].
Elevated SPARC mRNA and protein expression has
been observed in endothelial cells involved in angiogen-
esis [18, 45]. Bovine aortic and human microvascular
endothelial cells that spontaneously form tube-like vessel
structures revealed that new vessel branches are
enriched in SPARC and possess a high mitotic index.
Confocal microscopy in an in vivo model of angiogen-
esis similarly showed intense SPARC staining in small-
caliber, newly formed, blood vessels and negligible
Fig. 5 SPARC influences hCMEC/D3 barrier function measured
by TEER and permeability. a Confluent hCMEC/D3 on transwell
inserts were replenished with media containing rh-SPARC (0.01,
0.1, 1, 10 μg/ml) for 24 h then tested for TEER and transendothelial
diffusion of FITC-labeled dextran (3 and 10 kDa). Compared to
the untreated conditions, TEER measurements reflect a dose-
dependent reduction in electrical impedance with increasing
rh-SPARC concentration reaching significance with 1 μg/ml or
greater rh-SPARC. Permeability assays using b 3 and c 10 kDa
FITC-dextran revealed exposure of hCMEC/D3 to 0.1–10 μg/ml
rh-SPARC enhanced permeability to both by 24 h of exposure.
One-way ANOVA and Tukey’s multiple comparison test vs.
untreated controls, *P < 0.05
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staining in larger developmentally mature vessels [17, 36].
In the heart, SPARC coincided with blood vessel neo-
vascularization on aortic valves yet not normal avascular
valves [46]. Notably, SPARC expression was upregulated
4.2-fold in bovine aortic endothelial cells and 10-fold in
rat cerebral endothelial cell (RVEC) cultures that spontan-
eously organized into capillary tubes in vitro [17, 21, 36],
suggesting a role for SPARC in “de novo” morphogenesis
of new microvessel angioarchitecture (vasculogenesis) and
the growth of new vessels from established ones (angio-
genesis). Taken together, these data suggest SPARC is
highly expressed in developmentally new blood vessels
undergoing angiogenesis in vivo, consistent with our in
vitro data showing that SPARC expression in human cere-
bral endothelia corresponds with proliferation and the ini-
tial steps of brain microvessel formation.
SPARC expression in vivo coincides with developing
blood vessels during embryogenesis and postnatal devel-
opment, but not in mature blood vessels of the normal
adult CNS. To that effect, in situ hybridization showed
SPARC mRNA levels enriched in migrating endothelia
and pia-derived blood vessels of embryonic and postna-
tal tissue progressively down-regulated with maturity in
adult cerebrovasculature [22, 23, 33, 47]. In the normal
(unlesioned) adult CNS, SPARC protein expression is
predominantly restricted to neurogenic subventricular
zones, choroid plexus, actively surveying microglia, spe-
cialized radial glia (Bergmann and Müller glia), and as-
trocytes [23, 34]. These data together suggest SPARC may
be expressed by cerebral endothelia in a spatiotemporal
manner consistent with a role in CNS vascularization.
Regulation of SPARC expression during inflammation
Human microvascular blood vessels express elevated
levels of SPARC at sites of injury, infection, and neoplasia
relative to healthy tissue [28, 33, 44, 48]. Expression of
SPARC in adult tissue and plasma increases in response to
various environmental stressors, including heat shock,
heavy metal toxicity, endotoxin [49], angiogenesis [21, 36],
and wound repair [20]. Using an in vitro model of the
BBB, this study offers the first description of inflammatory
regulation of SPARC expression in cerebral endothelia. In
the present study, the hCMEC/D3 cells exposed to the
prototypical injury response cytokine TNF-α and the
endotoxin LPS increased SPARC levels compared to the
untreated cells. Notably, IFN-γ combined with TNF-α
abrogated the SPARC induction otherwise observed in
response to TNF-α alone, suggesting cross-talk between
Fig. 6 SPARC and TNF-α regulate hCMEC/D3 tight junction protein expression. a Confluent hCMEC/D3 cultures treated with SPARC (0.1, 1, 10 μg/ml)
or TNF-α (200 U/ml) for 24 h were analyzed for tight junction (TJ) expression. TJ expression was quantified by immunoblot analysis of hCMEC/D3
lysates with the TJ-negative human astrocytoma cell line (Astro) ccf-sttg1 (Sigma) lysate as a negative control. A reduction in endothelial TJ expression
was observed with increasing SPARC exposure above 1 μg/ml. b Increasing exogenous SPARC from 0.1 to 1 μg/ml lowered both ZO-1 (by 23 %) and
occludin (by 20 %) expression. The bars represent the mean expression from 5 (ZO-1) and 4 (occludin) experiments, and error bars represent the SEM.
**P < 0.001; ***P < 0.0001 by ANOVA and Student-Newman-Keuls multiple comparisons test
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TNF-α and IFN-γ that may negatively regulate levels of
SPARC in response to inflammation at the BBB. Although
the present study is the first mention of pro-inflammatory
regulation of SPARC expression in cerebral endothelia,
other CNS injury models and neoplastic syndromes have
highlighted the association between inflammation and
SPARC-enriched blood vessels [48, 50].
In the normal adult CNS, SPARC levels are low and
expression is primarily restricted to astrocytes and
microglia of synaptic rich regions but typically not blood
vessels. That balance appears to shift during a number
of inflammatory states and models. In a cortical wound
model of CNS injury, SPARC mRNA was increased in
blood vessels proximal to the wound [33]. During the peak
phase of experimental autoimmune encephalomyelitis
(EAE), an animal model of the chronic inflammatory de-
myelinating disease MS, CD31-positive blood vessels be-
come intensely SPARC positive by immunohistochemistry
(Roskams Lab, unpublished observations). Extending be-
yond the vasculature to glial cells in close proximity, an-
other study demonstrated that up-regulation of SPARC
secreted by IFN-γ-treated astrocytes induced apoptosis
of myelin-specific autoreactive CD4+ T cells that other-
wise mediate the pathogenesis of EAE and MS, sugges-
ting a role for SPARC in protecting the CNS against
autoimmune-mediated damage during the course of
neuroinflammation (Hara et al.). Furthermore, increased
bioavailability of SPARC at the neurovascular niche may
promote CNS regeneration by supporting neurite out-
growth after neuronal injury [34].
Although the role of SPARC at sites of injury remains
to be fully characterized, experimental evidence suggests
SPARC promotes the effector phase of inflammation by
facilitating leukocyte transmigration. A study using HUVEC
and primary lung and cardiac endothelial cell cultures
demonstrated that SPARC is a VCAM1 (vascular cell
adhesion molecule) ligand that induces cytoarchitectural
rearrangement and intercellular gap formation, two pro-
cesses critical for leukocyte trafficking [38]. In SPARC-null
mice, inflammatory recruitment of neutrophils,
eosinophils, and monocytes/macrophages to an in-
flamed peritoneum was compromised compared to
those of the wildtype [38]. To that effect, SPARC-null
mice immunized with myelin oligodendrocyte glycopro-
tein (MOG35–55) exhibited delayed onset and reduced
severity of EAE, consistent with milder demyelination
and immune infiltration, as observed by histopatho-
logical examination [51]. These findings support the ar-
gument that regulation of SPARC expression may play
a key role in the mediation of inflammation through its
influence on immune trafficking into inflamed tissue.
This study reports that two inflammatory molecules,
TNF-α and LPS, increase SPARC expression in human
cerebral endothelial cells enriching SPARC bioavailability
at the neurovascular niche. Astrocyte-derived SPARC
was recently shown to specifically antagonize the synap-
togenic effect of SPARC-like 1 and decrease the number
of axosomatic synapses in contact with lumbar spinal
motor neurons, worsening the severity of paralysis during
EAE in mice [52]. In both remitting and non-remitting
EAE models, SPARC-like 1/SPARC mRNA and protein
ratios inversely correlated with clinical paralysis severity
scores. Decreased SPARC-like 1/SPARC ratios also corre-
sponded with diminished expression of presynaptic and
postsynaptic proteins as well as the number of axosomatic
synaptic contacts. In vitro experiments using cortical
astrocytes further revealed that T cell derived pro-
inflammatory cytokines including TNF-α and IL-17
inhibit SPARC-like 1 and promote SPARC expression,
favoring synaptic retraction, while anti-inflammatory
cytokines such as IL-10 did the opposite thus shifting
the ratio towards synaptic stabilization [52]. These data
taken together support a model whereby SPARC up-
regulation by pro-inflammatory cytokines drives motor
synaptic disassembly, contributing to neurological defi-
cits during the course of neuroinflammation. Indeed,
our study provides in vitro evidence that cerebral endo-
thelial cells are an abundant source of SPARC at the
neurovascular niche when exposed to pro-inflammatory
cytokines or bacterial endotoxin. During development,
elimination of excess synaptic contacts is thought to re-
fine circuit function [53]; however, whether this is an
adaptive or maladaptive response in the context of CNS
inflammation is unclear. It is thus reasonable to con-
tend that regulation of endothelial-derived SPARC
under inflammatory conditions may contribute to tran-
sient paralysis and neurological dysfunction by destabi-
lizing synapses in the presence of neuroinflammation.
SPARC regulation of BBB integrity and permeability
As BBB disruption is among the earliest events in several
CNS pathologies such as MS, we examined the influence
of SPARC on barrier function and TJ expression using
an in vitro BBB model. The involvement of SPARC
in the development, maintenance, and breakdown of
blood-neural barriers is implicated by its spatiotemporal
localization at the BBB and blood-cerebral spinal fluid
barrier (BCSFB) during development and inflammation.
Ependymal cells of the BCSFB lining brain ventricles
and the choroid plexus express SPARC during embryo-
genesis and postnatal development but limit expression
with maturity to barrier sites of the lateral ventricle in
adult mice [23]. Analogously, brain endothelial cells of
developing blood vessels arising from the pia mater
strongly express SPARC during embryogenesis but
down-regulate it during early postnatal development as
they mature and establish a BBB [22]. In adult mice,
SPARC is concentrated in mature astrocytic endfeet of
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the BBB [23]. Astrocytes and the soluble mediators they
produce can up-regulate TJ and transporter expression
on brain endothelia and are thought to be major regula-
tors of BBB development [2, 54]. The localization of
SPARC to astrocytic endfeet and cerebral endothelia
place SPARC in an ideal niche to induce, maintain, or
disrupt blood-neural barrier characteristics [11]. SPARC
in astrocytic endfeet could reflect an uptake of endothelial-
derived SPARC, an accumulation of astrocyte-derived
SPARC into its end feet, or both.
TJ protein levels were quantified in lysates from con-
fluent hCMEC/D3 cultures treated for 24 h with various
doses of rh-SPARC or rhTNF-α. The reduction of TJ
protein expression provides the first documentation of
SPARC regulation of TJ modulation in endothelial cells.
An important initial consideration, here, is the physio-
logical relevance of SPARC doses used. In normal
healthy individuals, cerebral endothelial cells reside in
plasma concentrations of SPARC between 0.1 and 0.8
μg/ml, while increased concentrations have been associ-
ated with pathological conditions such as neoplasia,
trauma, heart, and kidney diseases [25, 27, 30, 31]. In
our experiments, elevated SPARC concentrations, mod-
eling that expected during inflammation, lowered ZO-1
and occludin expression, suggesting that SPARC may in-
deed be involved in mediating TJ loss and associated
BBB breakdown at supraphysiological levels. Functional
assays performed in parallel showed that increasing con-
centrations of recombinant human SPARC applied ex-
ogenously increased transendothelial permeability of cell
monolayers as evidenced by increased dextran diffusion
and decreased TEER impedence. TNF-α applied exogen-
ously as a positive control decreased total expression of
all TJ proteins studied, consistent with previous reports
in the literature [4, 8, 14]. Hydrocortisone offered some
protection against the reduction of ZO-1 but not occlu-
din. This may be explained by a greater ability of hydro-
cortisone to drive ZO-1 expression than occludin in
hCMEC/D3 cultures [4].
The prevailing understanding from these experiments
was that SPARC increases transendothelial permeability
and disrupts endothelial barrier function in vitro
through its effect on the relative state of endothelial dif-
ferentiation. SPARC has also been shown to modulate
transendothelial permeability through protein tyrosine
kinase (PTK) phosphorylation signaling. The potent PTK
inhibitor, herbimycin A, diminished SPARC-induced
changes in permeability. A marked 12-fold increase in
phosphotyrosine-containing proteins was immunoloca-
lized to interendothelial borders within 1 h of SPARC
treatment concomitant to barrier opening as evidenced
by immunocytochemistry and BSA diffusion permeability
assay, respectively. These findings are consistent with our
data demonstrating decreased TJ expression and increased
barrier permeability in SPARC-treated hCMEC/D3
monolayers, suggesting a putative role for SPARC in
neurological conditions such as MS, characterized by
microvascular TJ loss and barrier disruption [10]. Clearly,
SPARC has the potential to influence BBB integrity, but
the exact nature and outcome of this influence—be it
reparative or pathological—is yet to be determined.
In the present study, SPARC concentrations expected
during angiogenesis, inflammation, and wound repair
lowered ZO-1 and occludin expression and increased
endothelial barrier permeability. TJ depletion is one
mechanism conventionally associated with BBB break-
down in diseases such as MS. VEGF-induced BBB break-
down is associated with occludin down-regulation and
severe disability in EAE [9]. Transient global cerebral
ischemia diminished SPARC mRNA expression and
depleted SPARC in the basement membranes of laser-
captured microdissected (LCM) blood vessels after 24 h
of reperfusion [7]. Functional assays showed that the
post-ischemic cerebral microvessels were more perme-
able than the control vessels. Here, mild post-ischemic
hypothermia (~33 °C) attenuated loss of SPARC content
in the basement membrane and protected against BBB
breakdown, suggesting that the release of SPARC from
the basement membrane was responsible for barrier
opening. In this setting, SPARC released from the base-
ment membrane after ischemic injury could act in an
autocrine/paracrine manner and drive barrier disruption
and vessel leakiness through endothelial VCAM1 signal-
ing. In a recent article, tumor-derived SPARC was found
to trigger endothelial paracellular permeability in primary
human umbilical vein endothelial cell (HUVEC) mono-
layers via VCAM1 and p38 signaling, thus disrupting
endothelial monolayer integrity [55]. Taken together,
our study establishes SPARC as a novel regulator of
paracellular cerebrovascular permeability and TJ expres-
sion, revealing a targetable interaction in CNS pathology
for prevention of barrier disruption.
Conclusions
In summary, we describe elevated SPARC expression in
cerebral endothelial cells under developmental condi-
tions modeling angiogenesis and differential regulation
in the presence of inflammatory cytokines TNF-α, IFN-γ,
and the bacterial endotoxin LPS. Exposure to SPARC
at levels greater than those observed under normal
physiological conditions increases barrier permeability
and decreases TJ expression of ZO-1 and occludin.
Microvascular endothelial cell exposure to SPARC may
contribute to pathological processes in the CNS or fa-
cilitate its response to injury. Our study defines SPARC
as an attractive target for further scientific inquiry with
regard to its role in both pathological and potentially
reparative processes at the neurovascular niche.
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Additional file
Additional file 1: Figure S1. Subconfluent hCMEC/D3 regions exhibit
more intense SPARC expression than confluent regions by regional
immunocytochemistry analysis. SPARC intensity was measured in mean
pixel intensity (MPI ± SD) for selected cell-covered regions. SPARC staining in
the subconfluent cultures (3.85 ± 0.49, n = 21 images, 7 from each triplicate
well) was greater than that in the confluent cultures (2.83 ± 0.43, n = 14
images, 7 from each duplicate well). Bars represent the average of results
from n = 21 and n = 14 images, respectively. Error bars represent SD. Data
were analyzed for regional SPARC MPI in one experiment. Mann-Whitney
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